Inhibitory effects of nobiletin and its major metabolites on lung tumorigenesis
- 7 October 2019
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 10 (11) , 7444-7452
Abstract
The present study demonstrated that the oral administration of nobiletin significantly inhibited lung carcinogenesis in mice, and these chemopreventive effects could be attributed to its metabolites that showed potent anti-cancer effects.Keywords
Funding Information
- U.S. Department of Agriculture
- National Natural Science Foundation of China (31701600)
- Natural Science Foundation of Anhui Province (1808085QC77)
- Anhui Agricultural University
- China Scholarship Council
This publication has 55 references indexed in Scilit:
- Lycorine induces cell-cycle arrest in the G0/G1 phase in K562 cells via HDAC inhibitionCancer Cell International, 2012
- The Risk of Lung Cancer Related to Dietary Intake of FlavonoidsNutrition and Cancer, 2012
- Synergistic Anti-inflammatory Effects of Nobiletin and Sulforaphane in Lipopolysaccharide-Stimulated RAW 264.7 CellsJournal of Agricultural and Food Chemistry, 2012
- Metabolic conversion of dietary flavonoids alters their anti-inflammatory and antioxidant propertiesFree Radical Biology and Medicine, 2011
- Nobiletin Attenuates VLDL Overproduction, Dyslipidemia, and Atherosclerosis in Mice With Diet-Induced Insulin ResistanceDiabetes, 2011
- Effects of Nobiletin on PhIP-Induced Prostate and Colon Carcinogenesis in F344 RatsNutrition and Cancer, 2011
- Cell cycle, CDKs and cancer: a changing paradigmNature Reviews Cancer, 2009
- Inhibition of Adenoma Progression to Adenocarcinoma in a 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone–Induced Lung Tumorigenesis Model in A/J Mice by Tea Polyphenols and CaffeineCancer Research, 2006
- Determination of polymethoxylated flavones in peels of selected Jamaican and Mexican citrus (Citrus spp.) cultivars by high‐performance liquid chromatographyBiomedical Chromatography, 2006
- Promoting apoptosis as a strategy for cancer drug discoveryNature Reviews Cancer, 2005